Tolfedine 4% Solution for Injection for Use in Dogs and Cats

Страна: Велика Британія

мова: англійська

Джерело: VMD (Veterinary Medicines Directorate)

Активний інгредієнт:

Tolfenamic Acid

Доступна з:

Vetoquinol UK Ltd

Код атс:

QM01AG02

ІПН (Міжнародна Ім'я):

Tolfenamic Acid

Фармацевтична форма:

Solution for injection

Тип рецепту:

POM-V - Prescription Only Medicine – Veterinarian

Терапевтична група:

Cats, Dogs

Терапевтична области:

Anti Inflammatory NSAID

Статус Авторизація:

Authorized

Дата Авторизація:

1993-10-15

Характеристики продукта

Revised: October 2023
AN: 01785/2023
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Tolfedine 4% w/v Solution for Injection for dogs and cats
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance
Tolfenamic acid
40mg
Excipients
Benzyl alcohol
10.4mg
Sodium formaldehyde sulphoxylate
5mg
For a full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM
Sterile solution for injection
A clear colourless to slightly yellow sterile aqueous solution
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs, cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
IN DOGS: inflammatory and painful post operative syndromes.
IN CATS: adjuvant treatment of upper respiratory disease in
association with
antimicrobial therapy
4.3 CONTRA-INDICATIONS
Tolfenamic acid is contra-indicated in case of cardiac disease
Do not use in animals with impaired hepatic function or acute renal
insufficiency
Tolfenamic acid is contra-indicated in case of ulceration or digestive
bleeding, in case
of blood dyscrasia or hypersensitivity to tolfenamic acid.
Do not inject intramuscularly in cats.
Revised: October 2023
AN: 01785/2023
Page 2 of 6
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
NSAIDS can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory conditions associated with bacterial infections
appropriate concurrent
antimicrobial therapy should be instigated
The use of insulin-type needle/syringe is advisable particularly in
low-weight animals
to ensure an accurate dose.
4.5 SPECIAL PRECAUTIONS FOR USE
i. Special precautions for use in animals
Use in animals less than 6 weeks of age, or in aged animals, may
involve additional
risk. If such a use cannot be avoided animals may
require a reduced dosage and
careful clinical management is essential.
Reduced metabolism and excretion
in these animals should be
considered.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a
potential risk of increased renal toxicity.
Concurrent administr